Discontinuing Stimulants in Underweight Adults: BMI Threshold
There is no established BMI threshold for discontinuing stimulants in underweight adults, as current guidelines address stimulants exclusively for obesity treatment (BMI ≥27-30 kg/m²), not for ADHD or other psychiatric indications where weight loss is an adverse effect rather than a therapeutic goal.
Critical Context: Guidelines Address Different Clinical Scenarios
The available evidence creates a fundamental mismatch with your question:
- Obesity guidelines 1, 2, 3, 4 recommend stimulants (phentermine, diethylpropion) specifically to induce weight loss in patients with BMI ≥30 kg/m² or ≥27 kg/m² with complications
- ADHD treatment guidelines 5 discuss stimulant side effects including appetite suppression and weight loss, but provide no BMI cutoffs for discontinuation
- The evidence focuses on when to start stimulants for obesity, not when to stop them for excessive weight loss
Clinical Approach Based on General Medical Principles
When to Consider Discontinuation
Since guidelines don't address this scenario, apply standard underweight risk thresholds:
BMI < 18.5 kg/m² warrants serious concern and medication reassessment:
- This defines clinical underweight with increased morbidity/mortality risk
- Nutritional deficits become clinically significant 6
- Metabolic complications emerge
BMI < 17.0 kg/m² represents severe underweight requiring urgent intervention:
- Substantially elevated mortality risk
- Organ dysfunction risk increases
- Medication discontinuation should be strongly considered
Monitoring Strategy Beyond BMI
Track these parameters monthly in at-risk patients:
- Rate of weight loss: >5% body weight in 3 months is clinically significant
- Nutritional markers: albumin, prealbumin, micronutrient levels
- Functional status: energy levels, exercise tolerance, daily activities
- Hormonal disruption: menstrual irregularities in women, testosterone in men
- Cardiovascular parameters: orthostatic hypotension, bradycardia
Management Algorithm
BMI 18.5-20 kg/m² with ongoing weight loss:
- Reduce stimulant dose by 25-50%
- Implement aggressive nutritional support
- Weekly weight monitoring
- Consider alternative medications with less appetite suppression
BMI < 18.5 kg/m²:
- Discontinue stimulant immediately if weight loss continues
- Switch to non-stimulant alternatives (atomoxetine, bupropion with caution, guanfacine)
- Refer to nutrition specialist
- Address underlying eating behaviors
BMI < 17.0 kg/m²:
- Discontinue stimulant
- Medical evaluation for complications
- Consider inpatient nutritional rehabilitation if indicated
Important Caveats
Stimulant effects on weight are complex 6: The mechanism isn't simply appetite suppression—stimulants alter ghrelin, leptin, and metabolic homeostasis, potentially causing long-term dysregulation of energy balance even after discontinuation.
Pediatric data cannot be extrapolated 7, 8, 9: Studies show children with underweight have higher stimulant discontinuation rates, but developmental physiology differs fundamentally from adults.
Individual variation matters: Some patients maintain stable low BMI on stimulants without complications, while others develop metabolic deficits at higher BMIs. Clinical judgment must incorporate functional status, not just numbers.
The obesity pharmacotherapy guidelines 1, 2, 3, 10, 3 that dominate the evidence base are irrelevant to your question—they recommend starting stimulants at BMI ≥27 kg/m² to cause weight loss, the opposite clinical scenario.